Sapanisertib
As of the edition of 20 October 2026, Sapanisertib is a small molecule: in active development; acts on MTOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 50, 12 stopped early
- Disease areas
- Cancer; Blood and lymph; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Sapanisertib.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MTOR | Serine/threonine-protein kinase mTOR | P42345 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 21 | 13 | 3 | 5 |
| Phase 2 | 29 | 14 | 7 | 7 |
| All trials | 50 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Takeda | Lead sponsor of trials | 2010 to now |
| Calithera Biosciences | Lead sponsor of trials | 2014 to now |
| Sensei Biotherapeutics | Lead sponsor of trials | 2022 to now |